$CLDI

Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering SAN DIEGO, September 17, 2026 – Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines,

Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting fi

Calidi Biotherapeutics (NYSE: CLDI) shares rose after the company recapped 2026 progress and outlined upcoming milestones. Calidi said it held a successful pre-IND meeting with the FDA for CLD-401, discussed pharmacology, toxicology, CMC and phase I strategy, and is advancing in situ TCEs. It also added Corsee Sanders to the board and cut debt and G&A by about $1M in 1Q26 vs 1Q25.

Calidi Biotherapeutics (NYSE American: CLDI) reported a positive US FDA pre-IND outcome for CLD-401, agreeing on pharmacology, toxicology, CMC and phase I protocol strategy. The company targets first patient dosing in Q1 2027 and expects first data in Q2 2027. It also cited new RedTail in situ TCE data, added a board member, and cut G&A by about $1M from Q1 2025 to Q1 2026.

Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 GENESIS MOREHOUSE AT 5580 LEASE BP3-SD4 5580 MOREHOUSE DRIVE LLC, a Delaware limited liability company, as Landlord, and CALIDI BIOTHERAPEUTICS, INC., a Delaware corporation, as Tenant SUMMARY OF BASIC LEASE INFORMATION This Summary of Ba

Calidi Biotherapeutics (NYSE American: CLDI) said it appointed Corsee Sanders, Ph.D., an independent director, to its board effective June 17, 2026. Calidi cited her 30+ years in biopharma clinical operations, including leadership roles at Genentech/Roche and Celgene/Juno integration experience. The company said the move supports advancement of CLD-401 and its RedTail platform into the clinic.

Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001855485 0001855485 2026-06-17 2026-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001855485 0001855485 2026-06-12 2026-06-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) reported short interest fell to 670,614 shares as of May 15, down 77.9% from 3,038,967 on April 30, with 6.4% of shares sold short and a 0.3 days-to-cover ratio. The stock traded at $0.19, down 2.6%. The company reported EPS of -$0.43 for the quarter ended May 14, and institutional holders own 12.53%.

SAN DIEGO, Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Calidi Biotherapeutics, Inc. ( "Calidi" or the "Company" ) ( NYSE American: CLDI ) , a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, ...